Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). Data will be collected from each patient during the 6 months of induction treatment and for up to 3 years of follow-up.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Safety: Incidence of adverse events | 4.5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Response Rate (complete response + partial response) | 4.5 years | |
| Progression-free survival, defined as time from first treatment to lymphoma progression or death | 4.5 years | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Previously untreated diffuse large B-cell lymphoma or follicular lymphoma patients
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA) | Beijing | 100071 | China | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30058572 | Derived | Wu JQ, Song YP, Su LP, Zhang MZ, Li W, Hu Y, Zhang XH, Gao YH, Niu ZX, Feng R, Wang W, Peng JW, Li XL, Ouyang XN, Wu CP, Zhang WJ, Zeng Y, Xiao Z, Liang YM, Zhuang YZ, Wang JS, Sun ZM, Bai H, Cui TJ, Feng JF. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study. Chin Med J (Engl). 2018 Aug 5;131(15):1767-1775. doi: 10.4103/0366-6999.237401. | |
| 27460571 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Overall Survival, defined as time from 1st treatment to death of any cause |
| 4.5 years |
| the First Hospital of Jilin University |
| Changchun |
| 130021 |
| China |
| Xiangya Hospital of Centre-South University | Changsha | 410008 | China |
| Changzhou First People's Hospital | Changzhou | 213003 | China |
| Daqing Oilfield General Hospital | Daqing | 163001 | China |
| The First People's Hospital of Foshan | Foshan | China |
| Fuzhou General Hospital, PLA Nanjing Military Area Command | Fuzhou | 110016 | China |
| Fujian Provincial Hospital | Fuzhou | China |
| Nanfang Hospital, Southern Medical University | Guangzhou | 510515 | China |
| The affiliated Hospital of Guiyang Medical College | Guiyang | China |
| The Second Affiliated Hospital of Zhejiang University College | Hangzhou | 310009 | China |
| Anhui Province Cancer Hospital | Hefei | 12345 | China |
| Affiliated Hospital of Inner Mongolia Medical College | Hohhot | China |
| Shandong Cancer Hospital | Jinan | 250117 | China |
| The First Affilliated Hospital of Kunming Medical College | Kunming | 650032 | China |
| Lanzhou General Hospital, PLA Lanzhou Military Area Command | Lanzhou | 730050 | China |
| Jiangsu Cancer Hospital | Nanjing | 210009 | China |
| Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province) | Shijiazhuang | 050035 | China |
| Shanxi Province Cancer Hospital | Taiyuan | China |
| Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology | Wuhan | 430022 | China |
| The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital) | Xi'an | 710038 | China |
| Henan Cancer Hospital | Zhengzhou | 450008 | China |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou | 450052 | China |
| Zhongshan General Hospital | Zhongshan | 528403 | China |
| Derived |
| Wu J, Song Y, Su L, Xu L, Chen T, Zhao Z, Zhang M, Li W, Hu Y, Zhang X, Gao Y, Niu Z, Feng R, Wang W, Peng J, Li X, Ouyang X, Wu C, Zhang W, Zeng Y, Xiao Z, Liang Y, Zhuang Y, Wang J, Sun Z, Bai H, Cui T, Feng J. Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study. BMC Cancer. 2016 Jul 26;16:537. doi: 10.1186/s12885-016-2523-7. |
| ID | Term |
|---|---|
| D016403 | Lymphoma, Large B-Cell, Diffuse |
| ID | Term |
|---|---|
| D016393 | Lymphoma, B-Cell |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided